Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.

by James Crespo, Hongxia Sun, Jimin Wu, Qing-Qing Ding, Guilin Tang, Melissa K Robinson, Hui Chen, Aysegul A Sahin, Bora Lim
Published 2020-01-01